辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PFE 辉瑞

交易中 07-26 11:15:49 EDT

30.61

+0.85

+2.86%

最高30.71	最低30.02	成交量1,396万
今开30.15	昨收29.76	日振幅2.32%
总市值1,735亿	流通市值1,732亿	总股本56.67亿
成交额4.25亿	换手率0.25%	流通股本56.59亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"PFE","market":"US","secType":"STK","nameCN":"辉瑞","latestPrice":30.61,"timestamp":1722006948749,"preClose":29.76,"halted":0,"volume":13958753,"delay":0,"floatShares":5658544636,"shares":5666592898,"eps":-0.05851,"marketStatus":"交易中","marketStatusCode":2,"change":0.85,"latestTime":"07-26 11:15:49 EDT","open":30.15,"high":30.71,"low":30.02,"amount":425430993.400666,"amplitude":0.023185,"askPrice":30.61,"askSize":630,"bidPrice":30.6,"bidSize":1971,"shortable":3,"etf":0,"ttmEps":-0.05851,"exchange":"NYSE","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1722024000000},"adr":0,"listingDate":-819144000000,"adjPreClose":29.76,"adrRate":0,"dividendRate":0.053904,"preHourTrading":{"tag":"盘前","latestPrice":30.18,"preClose":29.76,"latestTime":"09:29 EDT","volume":243086,"amount":7286553.411888,"timestamp":1722000594502},"postHourTrading":{"tag":"盘后","latestPrice":30.26,"preClose":30.18,"latestTime":"19:59 EDT","volume":4912080,"amount":148272673.588,"timestamp":1721951970474},"volumeRatio":1.476574,"optionData":{"bulkOrders":[{"symbol":"PFE","call":false,"expireDate":1726804800000,"strike":"29.0","timestamp":1722005089070,"price":0.550000011920929,"volume":5000,"amount":275000,"type":"+"},{"symbol":"PFE","call":true,"expireDate":1726804800000,"strike":"29.0","timestamp":1722005089070,"price":2.309999942779541,"volume":5000,"amount":1155000,"type":"+"}]},"impliedVol":0.3283,"impliedVolPercentile":0.9365},"requestUrl":"/m/hq/s/PFE/tweets","defaultTab":"tweets","newsList":[{"id":"2454132329","title":"辉瑞上涨3.09%，报30.68美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2454132329","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454132329?lang=zh_cn&edition=full","pubTime":"2024-07-26 22:59","pubTimestamp":1722005997,"startTime":"0","endTime":"0","summary":"7月26日，辉瑞(PFE)盘中上涨3.09%，截至22:59，报30.68美元/股，成交3.91亿美元。财务数据显示，截至2024年03月31日，辉瑞收入总额148.79亿美元，同比减少19.51%；归母净利润31.15亿美元，同比减少43.8%。大事提醒：7月30日，辉瑞将于(美东)盘前披露2024财年中报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/07/26225941852475.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["IE00B19Z3B42.SGD","LU0170899867.USD","LU0122379950.USD","BK4585","SG9999002232.USD","LU1066053197.SGD","BK4007","IE00BBT3K403.USD","LU1883839398.USD","SG9999011175.SGD","SG9999001176.USD","PFE","LU0058720904.USD","IE00BLSP4452.SGD","LU0234572021.USD","BK4581","SG9999001176.SGD","LU1066051498.USD","BK4534","LU0868494617.USD","LU0321505868.SGD","BK4550","LU1894683264.USD","LU0456855351.SGD","LU1023059063.AUD","SG9999003800.SGD","SG9999013999.USD","IE0002270589.USD","LU0321505439.SGD","IE00B19Z3581.USD","SG9999002224.SGD","BK4588","BK4533","LU1894683348.USD","LU0289739699.SGD","BK4568","BK4592","IE00BLSP4239.USD","SGXZ57979304.SGD","LU1057294990.SGD"],"gpt_icon":1},{"id":"2454237883","title":"辉瑞公司  预计每股收益46美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2454237883","media":"Reuters","labels":["preview"],"top":-1,"share":"https://www.laohu8.com/m/news/2454237883?lang=zh_cn&edition=full","pubTime":"2024-07-26 22:14","pubTimestamp":1722003271,"startTime":"0","endTime":"0","summary":"   * 辉瑞公司   将于7月30日公布截至2024年6月30日的业绩报告，预计该公司的季度收入将有所增长。   * LSEG 分析师对辉瑞公司的平均预期为每股收益 46 美分。* 华尔街对辉瑞公司 12 个月目标价的中位数为 30.47 美元，高于上一次收盘价 30.18 美元。7月26日 - 上一季度业绩。除非另有说明，所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFE"],"gpt_icon":1},{"id":"2454314840","title":"礼来拐点？两日蒸发1000亿美金！辉瑞基因疗法获欧盟批准，罗氏诊断上半年营收近600亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2454314840","media":"医药经济报","labels":["Product Release","Business Data"],"top":-1,"share":"https://www.laohu8.com/m/news/2454314840?lang=zh_cn&edition=full","pubTime":"2024-07-26 18:16","pubTimestamp":1721988987,"startTime":"0","endTime":"0","summary":"辉瑞于2014年12月以2000万美元预付款从Spark Therapeutics获得该疗法。截止目前，KN057已经获得两项由FDA授予的孤儿药资格。目前，KN057正在中国开展两项3期临床研究。礼来两日蒸发1000亿美金7月25日以来，全球市值最高的药企礼来制药的市值蒸发了1000亿美元。如不及时治疗，会造成受累脏器的不可逆损害，最终导致患者死亡。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240726183128955d2a9f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240726183128955d2a9f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LLY","PFE"],"gpt_icon":1},{"id":"1124744791","title":"期权大单丨英伟达期权成交激增，多空双方博弈激烈；福特汽车绩后暴跌Put单大赚","url":"https://stock-news.laohu8.com/highlight/detail?id=1124744791","media":"老虎资讯综合","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/1124744791?lang=zh_cn&edition=full","pubTime":"2024-07-26 10:30","pubTimestamp":1721961000,"startTime":"0","endTime":"0","summary":"英伟达当日期权成交649.61万张合约，较前一交易日增加51%，看涨期权占比60%。期权链上，多空双方博弈激烈，其中，本周五到期、115美元行使价的Call单成交量最高，有29.85万张，未平仓量1.93万张；而本周五到期、110美元行使价是成交量最大的Put单，有22.96万张，未平仓量3.89万张。其中于8月16日到期的24美元行使价的看涨期权成交居前，成交逾10万张。美国航空当日期权成交60.52万张合约，较90日均量放大5倍，其中看涨期权占比近40%。","market":"us","thumbnail":"https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["F","AAL","NVDA","PFE"],"gpt_icon":0},{"id":"2454337019","title":"早新闻 | 降息潮来了，降幅5至40基点！上海无人驾驶出租车预计8月开放","url":"https://stock-news.laohu8.com/highlight/detail?id=2454337019","media":"数据宝","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2454337019?lang=zh_cn&edition=full","pubTime":"2024-07-25 07:32","pubTimestamp":1721863920,"startTime":"0","endTime":"0","summary":"整体来看，本次调整的产品类型不仅包含3年期、5年期等中长期存款，还包含多类型中短期存款，存款利率降幅在5至40基点。上海无人驾驶出租车预计8月对公众开放据报道，赛可智能无人驾驶出租车 有望在8月对公众开放。公司2024年第三季度的营业收入环比增速预计高于上年同期的环比增速，第三季度营业利润率预计接近2023年下半年的平均水平。扣除非经常性损益后的净利润预计为750万元至900万元，上年同期亏损1,061.85万元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA4MDU0MzQ4Mg==&mid=2653365909&idx=4&sn=f023f5eddff2e31495adfa1664f846ba&chksm=85fb74823a9afc7b8c905f5073b236df6690b7dc98946f0ea616aae5079d698ce730aaecef7a&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK4007","IE00B19Z3B42.SGD","FDN","SG9999002232.USD","BK4585","LU1894683348.USD","LU0170899867.USD","SG9999003800.SGD","SGXZ57979304.SGD","IE0002270589.USD","IE00B19Z3581.USD","LU1057294990.SGD","LU1883839398.USD","LU0456855351.SGD","IE00BLSP4239.USD","LU1023059063.AUD","SG9999013999.USD","BK4550","BK4581","LU1066053197.SGD","PFE","LU1066051498.USD","SG9999001176.USD","LU0122379950.USD","BK4568","BK4592","SG9999011175.SGD","BK4534","IE00BLSP4452.SGD","LU0321505439.SGD","SG9999002224.SGD","LU0868494617.USD","SG9999001176.SGD","LU0234572021.USD","LU0321505868.SGD","BK4533","LU1894683264.USD","TSLA","NVDA","LU0058720904.USD","LU0289739699.SGD","BK4588","LCID","IE00BBT3K403.USD"],"gpt_icon":1},{"id":"2454383497","title":"辉瑞遗传性凝血障碍基因疗法后期试验成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2454383497","media":"华尔街见闻","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2454383497?lang=zh_cn&edition=full","pubTime":"2024-07-25 03:05","pubTimestamp":1721847930,"startTime":"0","endTime":"0","summary":"辉瑞公司周三宣布，其针对罕见遗传性凝血障碍——血友病A的实验性基因疗法，在一项大型的后期临床试验中取得了成功，为潜在获批铺平道路。而且继今年4月获批用于治疗B型血友病的“Beqvez”之后 ，这款A型血友病治疗药物可能成为该公司进入美国市场的第二种基因疗法。","market":"us","thumbnail":"https://wpimg-wscn.awtmt.com/1211de44-5df8-40d1-bc00-854c10cde7f9.jpeg","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/1211de44-5df8-40d1-bc00-854c10cde7f9.jpeg"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3720987","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3720987","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["LU0868494617.USD","SG9999002232.USD","IE00BLSP4239.USD","BK4533","LU0170899867.USD","SG9999011175.SGD","IE00BLSP4452.SGD","LU0321505868.SGD","LU1883839398.USD","LU1894683348.USD","SG9999001176.SGD","SG9999002224.SGD","BK4585","BK4581","BK4534","BK4568","SGXZ57979304.SGD","LU1057294990.SGD","PFE","LU1066053197.SGD","LU1894683264.USD","LU0234572021.USD","IE00B19Z3581.USD","LU0456855351.SGD","IE0002270589.USD","LU1066051498.USD","BK4588","BK4007","LU0122379950.USD","IE00BBT3K403.USD","LU0289739699.SGD","BK4550","SG9999013999.USD","SG9999001176.USD","LU0321505439.SGD","SG9999003800.SGD","LU1023059063.AUD","BK4592","LU0058720904.USD","IE00B19Z3B42.SGD"],"gpt_icon":1},{"id":"2454833959","title":"更新版 1-英国监管机构批准辉瑞-生物技术公司针对JN.1菌株的更新版COVID注射剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2454833959","media":"Reuters","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2454833959?lang=zh_cn&edition=full","pubTime":"2024-07-25 01:06","pubTimestamp":1721840803,"startTime":"0","endTime":"0","summary":"     路透7月24日 - 英国卫生监管机构周三表示，已批准辉瑞  和BioNTech公司  生产的针对JN.1亚变异株的更新版COVID-19疫苗用于婴儿、儿童和成人。该监管机构还表示将密切关注疫苗的安全性。在全球范围内，欧洲药品管理局和世界卫生组织等监管机构都建议 COVID 疫苗生产商更新其疫苗，以 JN.1 变体为目标，尽管美国食品和药物管理局建议 ，在可行的情况下以较新的 KP.2 变体为目标。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","BK4592","LU1894683348.USD","LU1023059063.AUD","LU0289739699.SGD","IE00BLSP4452.SGD","LU0234572021.USD","SG9999001176.SGD","LU0321505439.SGD","IE00B19Z3B42.SGD","LU1894683264.USD","LU0456855351.SGD","LU1057294990.SGD","SG9999013999.USD","SG9999011175.SGD","BK4534","IE0002270589.USD","PFE","BK4550","SG9999001176.USD","BK4581","IE00B19Z3581.USD","BK4007","LU0058720904.USD","BK4568","SG9999002232.USD","BK4585","LU1066053197.SGD","LU0321505868.SGD","LU1066051498.USD","SG9999002224.SGD","SGXZ57979304.SGD","SG9999003800.SGD","BK4588","LU0868494617.USD","IE00BLSP4239.USD","LU0122379950.USD","IE00BBT3K403.USD","LU0170899867.USD","LU1883839398.USD"],"gpt_icon":1},{"id":"2454887541","title":"英国监管机构批准辉瑞-生物技术公司注射JN.1 COVID变异体","url":"https://stock-news.laohu8.com/highlight/detail?id=2454887541","media":"Reuters","labels":["Product Release","Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2454887541?lang=zh_cn&edition=full","pubTime":"2024-07-25 00:08","pubTimestamp":1721837311,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透7月24日 - 英国卫生监管机构周三表示，已授权辉瑞  和BioNTech公司  生产的针对冠状病毒JN.1亚变异株的更新版COVID-19疫苗用于婴儿、儿童和成人。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGXZ57979304.SGD","BK4550","IE0002270589.USD","LU0321505868.SGD","BK4568","IE00BBT3K403.USD","PFE","LU1066051498.USD","LU0321505439.SGD","LU0058720904.USD","BK4588","LU0289739699.SGD","SG9999013999.USD","IE00BLSP4452.SGD","LU0234572021.USD","SG9999011175.SGD","BK4007","LU1023059063.AUD","SG9999001176.USD","IE00B19Z3B42.SGD","LU0868494617.USD","LU0170899867.USD","SG9999002232.USD","IE00BLSP4239.USD","BK4592","BK4581","LU1066053197.SGD","LU1057294990.SGD","LU0122379950.USD","LU0456855351.SGD","BK4585","SG9999001176.SGD","IE00B19Z3581.USD","BK4533","LU1894683348.USD","SG9999002224.SGD","BK4534","LU1883839398.USD","LU1894683264.USD","SG9999003800.SGD"],"gpt_icon":1},{"id":"2453886644","title":"辉瑞A型血友病基因疗法在后期试验中取得成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2453886644","media":"环球市场播报","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2453886644?lang=zh_cn&edition=full","pubTime":"2024-07-24 22:35","pubTimestamp":1721831700,"startTime":"0","endTime":"0","summary":"　　辉瑞公司周三表示，在一项大型后期试验中，该公司开发的一种针对罕见遗传性凝血障碍疾病的实验性基因疗法取得了成功，为可能的批准铺平了道路。　　这种被称为A型血友病疗法的基因疗法，可能成为该公司继Beqvez之后进入美国市场的第二种基因疗法。该公司的Beqvez于今年4月获准用于B型血友病。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/usstock/c/2024-07-24/doc-incfhatx9268698.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2024-07-24/doc-incfhatx9268698.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4533","BK4592","LU1894683348.USD","LU1023059063.AUD","LU0289739699.SGD","IE00BLSP4452.SGD","LU0234572021.USD","SG9999001176.SGD","LU0321505439.SGD","IE00B19Z3B42.SGD","LU1894683264.USD","LU0456855351.SGD","LU1057294990.SGD","SG9999013999.USD","SG9999011175.SGD","BK4534","IE0002270589.USD","PFE","BK4550","SG9999001176.USD","BK4581","IE00B19Z3581.USD","BK4007","LU0058720904.USD","BK4568","SG9999002232.USD","BK4585","LU1066053197.SGD","LU0321505868.SGD","LU1066051498.USD","SG9999002224.SGD","SGXZ57979304.SGD","SG9999003800.SGD","BK4588","LU0868494617.USD","IE00BLSP4239.USD","LU0122379950.USD","IE00BBT3K403.USD","LU0170899867.USD","LU1883839398.USD"],"gpt_icon":1},{"id":"2453527005","title":"辉瑞(PFE.US)A型血友病基因疗法在关键试验取得积极成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2453527005","media":"智通财经网","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2453527005?lang=zh_cn&edition=full","pubTime":"2024-07-24 19:44","pubTimestamp":1721821470,"startTime":"0","endTime":"0","summary":"辉瑞(PFE.US)治疗A型血友病的基因疗法在一项关键的后期试验中达到了目标，为该公司进入这个颇具挑战性的市场铺平了道路。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/source/image/93273.jpg?x-oss-process=image/format,jpg/quality,Q_100/resize,h_300","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/source/image/93273.jpg?x-oss-process=image/format,jpg/quality,Q_100/resize,h_300"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1155177.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4007","SG9999002232.USD","LU0170899867.USD","LU0122379950.USD","LU1883839398.USD","IE00B19Z3581.USD","LU1066053197.SGD","BK4581","LU0321505868.SGD","LU1894683264.USD","SGXZ57979304.SGD","SG9999001176.SGD","LU0058720904.USD","LU1023059063.AUD","IE00B19Z3B42.SGD","BK4533","BK4592","BK4588","IE0002270589.USD","SG9999001176.USD","BK4534","LU0321505439.SGD","BK4585","LU1894683348.USD","LU0456855351.SGD","SG9999013999.USD","BK4550","IE00BLSP4452.SGD","BK4568","LU1057294990.SGD","IE00BBT3K403.USD","LU0289739699.SGD","PFE","IE00BLSP4239.USD","SG9999003800.SGD","SG9999002224.SGD","SG9999011175.SGD","LU0234572021.USD","LU0868494617.USD","LU1066051498.USD"],"gpt_icon":1},{"id":"2453086003","title":"更新版 1-辉瑞公司的基因疗法在后期试验中降低了 A 型血友病的出血率","url":"https://stock-news.laohu8.com/highlight/detail?id=2453086003","media":"Reuters","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2453086003?lang=zh_cn&edition=full","pubTime":"2024-07-24 19:42","pubTimestamp":1721821351,"startTime":"0","endTime":"0","summary":"目前，A 型血友病患者的标准治疗方法是常规更换凝血因子 VIII。辉瑞公司表示，其 A 型血友病基因疗法不仅在降低患者年出血率方面达到了与因子 VIII 替代疗法相比无劣效性的主要目标，而且还显示出优于目前标准疗法的效果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IE00B19Z3B42.SGD","SG9999002232.USD","BK4585","LU1894683348.USD","LU0170899867.USD","SG9999003800.SGD","SGXZ57979304.SGD","IE0002270589.USD","IE00B19Z3581.USD","LU1057294990.SGD","LU1883839398.USD","LU0456855351.SGD","IE00BLSP4239.USD","LU1023059063.AUD","SG9999013999.USD","BK4550","BK4581","LU1066053197.SGD","LU1066051498.USD","SG9999001176.USD","LU0122379950.USD","BK4568","BK4592","SG9999011175.SGD","BK4534","IE00BLSP4452.SGD","LU0321505439.SGD","SG9999002224.SGD","LU0868494617.USD","SG9999001176.SGD","LU0234572021.USD","LU0321505868.SGD","BK4533","LU1894683264.USD","LU0058720904.USD","LU0289739699.SGD","BK4588","PFE","IE00BBT3K403.USD"],"gpt_icon":1},{"id":"2453077371","title":"晚期试验发现辉瑞公司的 A 型血友病基因疗法优于现有疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2453077371","media":"Reuters","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2453077371?lang=zh_cn&edition=full","pubTime":"2024-07-24 18:45","pubTimestamp":1721817904,"startTime":"0","endTime":"0","summary":"辉瑞公司的 Beqvez 作为治疗 B 型血友病的一次性基因疗法已于 4 月获得美国食品和药物管理局的批准 ，在美国的售价为 350 万美元。辉瑞公司说，其治疗甲型血友病的基因疗法不仅达到了与因子VIII替代疗法相比在降低患者年出血率方面无劣势的主要目标，而且还显示出优于目前的标准疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4533","BK4550","LU1066051498.USD","IE0002270589.USD","LU0234572021.USD","IE00BLSP4239.USD","LU0456855351.SGD","LU0289739699.SGD","BK4592","LU1894683264.USD","IE00BLSP4452.SGD","LU1023059063.AUD","BK4568","BK4585","LU1066053197.SGD","BK4534","LU0058720904.USD","BK4581","SG9999001176.SGD","BK4588","IE00B19Z3581.USD","LU0321505439.SGD","SG9999011175.SGD","LU0868494617.USD","LU0321505868.SGD","LU1894683348.USD","SG9999002224.SGD","PFE","IE00B19Z3B42.SGD","LU0170899867.USD","IE00BBT3K403.USD","LU0122379950.USD","SGXZ57979304.SGD","SG9999013999.USD","LU1883839398.USD","LU1057294990.SGD","SG9999003800.SGD","SG9999002232.USD","SG9999001176.USD"],"gpt_icon":1},{"id":"2453707882","title":"辉瑞(PFE.US)两款三抗在中国启动2期临床 治疗特应性皮炎","url":"https://stock-news.laohu8.com/highlight/detail?id=2453707882","media":"智通财经","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2453707882?lang=zh_cn&edition=full","pubTime":"2024-07-24 16:31","pubTimestamp":1721809919,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，7月23日，中国药物临床试验登记与信息公示平台显示，辉瑞在国内登记了一项Ⅱ期临床试验，以评估PF-07275315和PF-07264660在中度至重度特应性皮炎成人受试者中的疗效和安全性。其中，PF-07275315是一款靶向IL-4×IL-13×TSLP的三特异性抗体，PF-07264660是一款靶向IL-4×IL-13×IL-33的三特异性抗体。特应性皮炎是一种常见的慢性、复发性、炎症性皮肤病。辉瑞拟开发这两款三抗药物用于治疗特应性皮炎适应症。在海外，这两款在研新药此前已进入2期临床试验阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1154951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999011175.SGD","LU1894683348.USD","LU1023059063.AUD","SG9999013999.USD","LU0321505868.SGD","LU1894683264.USD","BK4588","IE00BLSP4239.USD","LU1066051498.USD","LU0234572021.USD","LU0321505439.SGD","LU0289739699.SGD","SG9999003800.SGD","IE00B19Z3581.USD","IE0002270589.USD","BK4550","SG9999002232.USD","BK4534","IE00BLSP4452.SGD","LU0456855351.SGD","SG9999001176.USD","LU1066053197.SGD","LU0058720904.USD","SG9999001176.SGD","LU0868494617.USD","LU1883839398.USD","BK4581","SG9999002224.SGD","IE00B19Z3B42.SGD","BK4592","LU0170899867.USD","IE00BBT3K403.USD","BK4568","BK4533","BK4007","SGXZ57979304.SGD","BK4585","PFE","LU1057294990.SGD","LU0122379950.USD"],"gpt_icon":1},{"id":"2453088130","title":"辉瑞(PFE)在新加坡投资7.43亿美元扩建工厂","url":"https://stock-news.laohu8.com/highlight/detail?id=2453088130","media":"金吾财讯","labels":["Business Data"],"top":-1,"share":"https://www.laohu8.com/m/news/2453088130?lang=zh_cn&edition=full","pubTime":"2024-07-23 16:53","pubTimestamp":1721724789,"startTime":"0","endTime":"0","summary":"金吾财讯 | 辉瑞(PFE)今日在新加坡经济发展局网站上发布声明称，辉瑞公司已投资10亿新元（7.43亿美元）扩建其在新加坡的活性药物成分自动化生产设施。这一扩建项目将在新加坡现有数百名员工的基础上，创造250多个新的高技能工作岗位。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210625/MjQ3ZTRjZTI0NDc3MWIxNzE1M2JmYTNmMTgxNzE4MTQwNjE1MDEzMzE4OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/MjQ3ZTRjZTI0NDc3MWIxNzE1M2JmYTNmMTgxNzE4MTQwNjE1MDEzMzE4OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"278087","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK6033","LU0868494617.USD","BK4568","LU0321505868.SGD","ES3.SI","LU0058720904.USD","LU1023059063.AUD","LU1066053197.SGD","BK4007","SG9999002232.USD","BK4533","IE00BLSP4452.SGD","LU0289739699.SGD","BK6523","SG9999001135.SGD","S68.SI","FSTM.SI","BK4588","BK4585","SG9999013999.USD","SGXZ57979304.SGD","IE0002270589.USD","SG9999011175.SGD","LU1066051498.USD","STI.SI","LU1883839398.USD","SG9999001176.SGD","LU0170899867.USD","SG9999000343.SGD","LU0205439572.USD","LU0898667661.SGD","FSTAS.SI","LU0122379950.USD","SG9999003800.SGD","LU0234572021.USD","BK4534","LU0321505439.SGD","BK4592","SG9999001176.USD","SG9999004360.SGD","SG9999002224.SGD","BK6516","LU1057294990.SGD","IE00BLSP4239.USD","IE00BBT3K403.USD","LU0456855351.SGD","LU0831103253.SGD","LU1119993845.HKD","PFE","IE00B19Z3B42.SGD"],"gpt_icon":1},{"id":"2453795432","title":"辉瑞下跌1.47%，报29.53美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2453795432","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453795432?lang=zh_cn&edition=full","pubTime":"2024-07-22 21:58","pubTimestamp":1721656697,"startTime":"0","endTime":"0","summary":"7月22日，辉瑞(PFE)盘中下跌1.47%，截至21:58，报29.53美元/股，成交4.92亿美元。财务数据显示，截至2024年03月31日，辉瑞收入总额148.79亿美元，同比减少19.51%；归母净利润31.15亿美元，同比减少43.8%。大事提醒：7月30日，辉瑞将于(美东)盘前披露2024财年中报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/07/22215841722311.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["LU1066053197.SGD","BK4585","LU0170899867.USD","LU1883839398.USD","IE00BBT3K403.USD","LU0321505868.SGD","LU0321505439.SGD","LU0456855351.SGD","SG9999001176.USD","IE00B19Z3B42.SGD","SG9999011175.SGD","LU0122379950.USD","IE0002270589.USD","LU1023059063.AUD","BK4533","LU1894683348.USD","PFE","LU0289739699.SGD","SG9999002224.SGD","LU0868494617.USD","IE00BLSP4239.USD","SG9999003800.SGD","SG9999013999.USD","BK4534","SGXZ57979304.SGD","BK4550","BK4568","LU1894683264.USD","IE00BLSP4452.SGD","SG9999002232.USD","SG9999001176.SGD","BK4581","LU1066051498.USD","BK4592","LU0058720904.USD","IE00B19Z3581.USD","LU1057294990.SGD","BK4588","LU0234572021.USD","BK4007"],"gpt_icon":1},{"id":"2453798225","title":"辉瑞中国区总裁、RDPAC执行委员会主席彭振科：加强与中国本土企业和科研机构的合作，促进全球医药产业链整合","url":"https://stock-news.laohu8.com/highlight/detail?id=2453798225","media":"每日经济新闻","labels":["Company Corporation"],"top":-1,"share":"https://www.laohu8.com/m/news/2453798225?lang=zh_cn&edition=full","pubTime":"2024-07-22 21:29","pubTimestamp":1721654970,"startTime":"0","endTime":"0","summary":"7月22日，作为在中国工作了十多年的跨国外资制药企业负责人，辉瑞中国区总裁、RDPAC（中国外商投资企业协会药品研制和开发工作委员会）执行委员会主席Jean-Christophe Pointeau（彭振科）认 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/usstock/20240722/c660042083.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/usstock/20240722/c660042083.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["PFE","159938"],"gpt_icon":1},{"id":"2453677457","title":"辉瑞中国区总裁、RDPAC执行委员会主席彭振科：加强与中国本土企业和科研机构的合作，促进全球医药产业链整合","url":"https://stock-news.laohu8.com/highlight/detail?id=2453677457","media":"每日经济新闻","labels":["Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2453677457?lang=zh_cn&edition=full","pubTime":"2024-07-22 20:45","pubTimestamp":1721652337,"startTime":"0","endTime":"0","summary":"7月22日，作为在中国工作了十多年的跨国外资制药企业负责人，辉瑞中国区总裁、RDPAC（中国外商投资企业协会药品研制和开发工作委员会）执行委员会主席Jean-ChristophePointeau（彭振科）认为，二十届三中全会聚焦高质量发展，强调科技创新和产业升级，与医药行业紧密相关。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202407223137017410.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202407223137017410.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00B19Z3B42.SGD","LU0170899867.USD","LU0122379950.USD","BK4585","SG9999002232.USD","LU1066053197.SGD","BK4007","IE00BBT3K403.USD","BK1515","LU1883839398.USD","SG9999011175.SGD","BK1574","PFE","SG9999001176.USD","LU0058720904.USD","IE00BLSP4452.SGD","LU0234572021.USD","BK4581","SG9999001176.SGD","09939","LU1066051498.USD","BK4534","LU0868494617.USD","LU0321505868.SGD","BK4550","LU1894683264.USD","LU0456855351.SGD","LU1023059063.AUD","SG9999003800.SGD","SG9999013999.USD","IE0002270589.USD","LU0321505439.SGD","IE00B19Z3581.USD","SG9999002224.SGD","BK4588","BK4533","LU1894683348.USD","BK1161","LU0289739699.SGD","BK4568","BK4592","IE00BLSP4239.USD","SGXZ57979304.SGD","LU1057294990.SGD"],"gpt_icon":1},{"id":"2452456634","title":"辉瑞下跌1.22%，报29.665美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2452456634","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452456634?lang=zh_cn&edition=full","pubTime":"2024-07-19 03:20","pubTimestamp":1721330443,"startTime":"0","endTime":"0","summary":"7月19日，辉瑞(PFE)盘中下跌1.22%，截至03:20，报29.665美元/股，成交10.19亿美元。财务数据显示，截至2024年03月31日，辉瑞收入总额148.79亿美元，同比减少19.51%；归母净利润31.15亿美元，同比减少43.8%。大事提醒：7月30日，辉瑞将于(美东)盘前披露2024财年中报。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/07/19032041662641.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK4007","IE00B19Z3B42.SGD","SG9999002232.USD","BK4585","LU1894683348.USD","LU0170899867.USD","SG9999003800.SGD","SGXZ57979304.SGD","IE0002270589.USD","IE00B19Z3581.USD","LU1057294990.SGD","LU1883839398.USD","LU0456855351.SGD","IE00BLSP4239.USD","LU1023059063.AUD","SG9999013999.USD","BK4550","BK4581","LU1066053197.SGD","LU1066051498.USD","SG9999001176.USD","LU0122379950.USD","BK4568","BK4592","SG9999011175.SGD","BK4534","IE00BLSP4452.SGD","LU0321505439.SGD","SG9999002224.SGD","LU0868494617.USD","SG9999001176.SGD","LU0234572021.USD","LU0321505868.SGD","BK4533","LU1894683264.USD","LU0058720904.USD","LU0289739699.SGD","BK4588","PFE","IE00BBT3K403.USD"],"gpt_icon":1},{"id":"2452122224","title":"生物医药企业CytoReason获8000万美元融资 英伟达与辉瑞参投","url":"https://stock-news.laohu8.com/highlight/detail?id=2452122224","media":"雷递网","labels":["Company Corporation"],"top":-1,"share":"https://www.laohu8.com/m/news/2452122224?lang=zh_cn&edition=full","pubTime":"2024-07-18 14:11","pubTimestamp":1721283094,"startTime":"0","endTime":"0","summary":"开发用于预测洞察的计算疾病模型的生物医药企业CytoReason日前宣布获8000万美元融资，投资放包括OurCrowd、英伟达（纳斯达克股票代码：NVDA）、辉瑞（纽约证券交易所代码：PFE）和赛默飞世尔科技（纽约证券交易所代码：TMO）。","market":"hk","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20240718/6385690869100530395594299.jpg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20240718/6385690869100530395594299.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.leinews.com/n27197/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["IE00BK4W5L77.USD","BK4568","BK4554","IE00B7KXQ091.USD","IE00BLSP4452.SGD","BK4579","BK4587","IE00B1BXHZ80.USD","LU0321505868.SGD","SG9999003800.SGD","IE00B5949003.HKD","IE00BYXW3230.USD","IE00BMPRXN33.USD","IE00BFSS8Q28.SGD","LU0056508442.USD","IE00BJLML261.HKD","SGXZ57979304.SGD","IE00BDRTCR15.USD","BK4550","GB00BDT5M118.USD","LU1883839398.USD","BK4007","IE0034235295.USD","IE00BHPRN162.USD","IE00B1XK9C88.USD","IE00B19Z8X17.USD","LU0456855351.SGD","IE00BJJMRY28.SGD","LU0289739699.SGD","NVDA","BK4543","LU0072462426.USD","IE0004445239.USD","IE0004445015.USD","SG9999001176.USD","IE00B19Z3581.USD","LU0061474960.USD","LU0053666078.USD","LU0170899867.USD","BK4534","IE00BFSS7M15.SGD","BK4585","PFE","IE00BKPKM429.USD","BK4141","LU1057294990.SGD","BK4503","IE00B19Z3B42.SGD","LU0061475181.USD","LU0069063385.USD"],"gpt_icon":1},{"id":"2452195541","title":"马克-库班的 Cost Plus 公司将进口青霉素以解决美国青霉素短缺问题","url":"https://stock-news.laohu8.com/highlight/detail?id=2452195541","media":"Reuters","labels":["Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2452195541?lang=zh_cn&edition=full","pubTime":"2024-07-18 02:31","pubTimestamp":1721241087,"startTime":"0","endTime":"0","summary":"    路透7月17日 - 马克-库班的Cost Plus药品公司周三表示，该公司正与美国食品和药物管理局合作，暂时在美国进口和分销青霉素。这家提供低价常用药品的网上药店将立即进口和分销120万单位的青霉素，以缓解辉瑞  青霉素L-A的短缺。古巴的 Cost Plus 公司将进口由葡萄牙 Laboratórios Atral S.A. 公司销售的Lentocilin 牌青霉素粉。Atral 公司在一份声明中说，Lentocilin 在美国只能凭处方购买，未经美国食品和药物管理局批准。Cost Plus公司没有立即回应路透的置评请求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","BK4550","BK4568","PFE","LU1023059063.AUD","IE00BBT3K403.USD","LU1066051498.USD","SG9999013999.USD","SG9999002224.SGD","BK4585","LU0321505439.SGD","LU0321505868.SGD","LU1894683348.USD","LU0058720904.USD","IE0002270589.USD","LU1057294990.SGD","LU0289739699.SGD","LU1883839398.USD","IE00BLSP4452.SGD","SG9999002232.USD","BK4592","SG9999001176.SGD","BK4533","IE00B19Z3B42.SGD","LU1066053197.SGD","SG9999001176.USD","LU0234572021.USD","SG9999011175.SGD","BK4007","LU1894683264.USD","LU0170899867.USD","LU0868494617.USD","LU0456855351.SGD","IE00BLSP4239.USD","SG9999003800.SGD","SGXZ57979304.SGD","BK4588","BK4534","BK4581","IE00B19Z3581.USD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.pfizer.com","stockEarnings":[{"period":"1week","weight":0.0158},{"period":"1month","weight":0.0782},{"period":"3month","weight":0.1882},{"period":"6month","weight":0.0987},{"period":"1year","weight":-0.1889},{"period":"ytd","weight":0.0483}],"compareEarnings":[{"period":"1week","weight":-0.0258},{"period":"1month","weight":-0.0118},{"period":"3month","weight":0.0593},{"period":"6month","weight":0.1046},{"period":"1year","weight":0.182},{"period":"ytd","weight":0.1328}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"辉瑞公司于1942年6月2日根据特拉华州法律成立。公司是一家以研究为基础的全球性生物制药公司。公司运用科学和全球资源，通过发现、开发、制造和分销保健产品（包括创新药物和疫苗），为人们带来延长和显著改善其生活的疗法。公司在发达国家和新兴市场开展工作，致力于促进健康、预防、治疗和治愈这个时代最令人恐惧的疾病。公司与医疗保健提供商、政府和当地社区合作，支持并扩大在全球范围内获得可靠、负担得起的医疗保健服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":0.00126},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.007167},{"month":3,"riseRate":0.613636,"avgChangeRate":0.015985},{"month":4,"riseRate":0.6,"avgChangeRate":0.019475},{"month":5,"riseRate":0.511111,"avgChangeRate":0.008757},{"month":6,"riseRate":0.488889,"avgChangeRate":0.00215},{"month":7,"riseRate":0.488889,"avgChangeRate":0.012194},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.000087},{"month":9,"riseRate":0.454545,"avgChangeRate":0.004027},{"month":10,"riseRate":0.659091,"avgChangeRate":0.014878},{"month":11,"riseRate":0.704545,"avgChangeRate":0.030213},{"month":12,"riseRate":0.5,"avgChangeRate":0.0093}],"exchange":"NYSE","name":"辉瑞","nameEN":"Pfizer"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供辉瑞(PFE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"辉瑞,PFE,辉瑞股票,辉瑞股票老虎,辉瑞股票老虎国际,辉瑞行情,辉瑞股票行情,辉瑞股价,辉瑞股市,辉瑞股票价格,辉瑞股票交易,辉瑞股票购买,辉瑞股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供辉瑞(PFE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}